The addition of the immune-checkpoint inhibitor nivolumab to first-line therapy with doxorubicin, vinblastine and dacarbazine seems feasible, with no signals of severe additional toxicities emerging. The high response rates and acceptable safety profile might make this combination an appealing alternative in the treatment of patients with high-risk disease.

中文翻译：

---

免疫检查点抑制作为霍奇金淋巴瘤的一线治疗。

在阿霉素，长春碱和达卡巴嗪的一线治疗中添加免疫检查点抑制剂nivolumab似乎是可行的，没有出现严重的其他毒性信号。高响应率和可接受的安全性可能使这种组合成为治疗高危疾病患者的诱人选择。